Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDBR 101
- Development stage
- Phase 2
- Lead developer
- U.S. Army Medical Research Institute of Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Percutaneous
01
Overview
NDBR 101 is a live-attenuated vaccine derived from the Live Vaccine Strain (LVS) of *Francisella tularensis*, the causative agent of tularemia. Developed and maintained by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), NDBR 101 refers to specific master seed lots used to produce the vaccine for high-risk personnel, such as laboratory workers and military specialists. The vaccine is typically administered via a multiple-puncture technique (scarification) using a bifurcated needle. It works by establishing a self-limiting infection that stimulates both humoral and cellular immune responses, providing protection against both naturally occurring tularemia and potential aerosolized exposure. Despite its long history of use under Investigational New Drug (IND) protocols, it remains an unlicensed investigational product due to requirements for further characterization and modernization of the manufacturing process.
- Other names
- Francisella tularensis LVSLive Vaccine StrainTularemia vaccine live attenuatedFrancisella tularensis vaccine live attenuated NDBR 101
Beyond the preview
Go deeper on NDBR 101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NDBR 101.